List of Byvalson drug patents

Byvalson is owned by Allergan.

Byvalson contains Nebivolol Hydrochloride; Valsartan.

Byvalson has a total of 2 drug patents out of which 0 drug patents have expired.

Byvalson was authorised for market use on 03 June, 2016.

Byvalson is available in tablet;oral dosage forms.

Byvalson can be used as method of treating hypertension.

The generics of Byvalson are possible to be released after 04 October, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803838 ALLERGAN Compositions comprising nebivolol
Aug, 2026

(3 years from now)

US7838552 ALLERGAN Compositions comprising nebivolol
Oct, 2027

(4 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in